DermaPrecise is an electronic multi-needle dermal injector to be used when consistent precision over depth, dose, and delivery matters. Owned by @RepliCel.
Joined October 2021
- Tweets15
- Following69
- Followers42
- Likes31
DermaPrecise retweeted
Hair loss is one of the most common conditions that dermatologists. Learn more:
bit.ly/3x66KQF #HairLossAwarenessMonth
The @RepliCel DermaPrecise Injector Shown to Produce Consistently High Cell Viability for Cell Therapy Injections. The Innovacell testing shows that DermaPrecise may greatly improve post-injection cell viability for injections into dermal or subcu tissue. accesswire.com/viewarticle.a…
As @replicel said, we're excited to share our first dermal injector data showing consistent injection and distribution in donated skin tissue. When injection precision matters, we believe @DermaPrecise will be the only and best solution for intra-dermal + sub-cutaneous injections
Well that didn't go as planned! We've corrected the press release from earlier today as we used the wrong image - one intended for an upcoming release. Here's the corrected release and image. We're very excited to share the first @dermaprecise data!
accesswire.com/viewarticle.a…
DermaPrecise retweeted
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing. accesswire.com/709732/Indepe… #dermtwitter #dermatology #dermalinjections #hairloss
DermaPrecise retweeted
The #eczema pipeline includes a number of biologic agents that target novel cytokines—IL-13 and IL-31. Watch April Armstrong, MD, MPH, discuss the evidence in this video: okt.to/70wXqF
#dermtwitter #dermatology
Another great injectible approved. This one (by @LEOHealthySkin) for the treatment of the very painful atopic dermatitis. We are actively exploring the benefits of controlled, highly reproducible and precise, multi-needle dispersion for such treatment protocols.
Leo Pharma announced the FDA approval of Adbry for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, clinical trial investigator gives his comments on this approval.
ow.ly/7men50HjIPV
DermaPrecise retweeted
The extracellular matrix under skin loses ~1% of its collagen per year. By age 45, we face ~25% collagen loss causing a loss of skin support structure and elasticity. RCS-01 is in development to stimulate new collagen production using a patient's own cells. #naturalregeneration
DermaPrecise retweeted
Very interesting article. There are so many variables with the MN and/or PRP techniques for hair loss. I do agree, a further research is needed. Thx for sharing.
A systematic review of microneedling for #hairloss - either standalone or in combination with other treatments like PRP. 22 clinical studies with 1127 subjects were evaluated. Hair parameters improved for a range of hair loss types. #openaccess
doi.org/10.1007/s13555-021-0…
DermaPrecise retweeted
Prior to his session at Dermatology Week, Dr Hassan Galadari discussed updates in neuromodulators and injectable fillers including considerations on how to go about the procedures. Watch his discussion here: okt.to/eirFut
#dermtwitter #cosmetic #dermatology
DermaPrecise retweeted
FDA In Brief: FDA Warns Public and Health Care Professionals Not to Use Needle-free Devices for Injection of Dermal Fillers
fda.gov/news-events/press-an…
It's not a product launch (yet) but its a product and we are pleased to be launching the trademark to start building pre-market awareness for the #dermalinjector we've developed for use with injections where precision matters. finance.yahoo.com/news/repli… @replicel @lifesciences_bc
We are very pleased to announce the name and trademark for the @RepliCel dermal injector.
DermaPrecise (tm) is an electronic multi-needle dermal injector to be used when consistent precision over depth, dose, and delivery matters.
biospace.com/article/release… via @biospace
